We expect Rafael Pharmaceuticals to report top line data from its AVENGER 500 Phase 3 registrational clinical trial in metastatic pancreatic cancer this calendar year We expect to submit our previously announced merger with Rafael Pharmaceuticals to our stockholders for a vote this calendar year The second and final interim futility analysis of Rafael Pharmaceuticals’ Phase 3 clinical trial in AML is planned for this calendar year On August 24, 2021, we closed a private investment in public...